Cencora — Feb 2, 2026 release

Healthcare Solutions Segment and improved results in Other as certain depreciable assets have been fully impaired as of December 31, 2025. As a result, Cencora is reaffirming its full fiscal 2026 adjusted diluted EPS guidance range. 2026 Guidance (1) Fiscal 2025 Actuals Revenue 7% to 9% growth $321.3B U.S. Healthcare Solutions Segment (2) 7% to 9% growth $285.0B International Healthcare Solutions Segment (2)(3) 7% to 9% growth $28.3B Other (2) 1% to 5% growth $8.2B Adjusted operating income 11.5% to 13.5% growth $4.2B U.S. Healthcare Solutions Segment (2) 14% to 16% growth $3.3B International Healthcare Solutions Segment (2)(3) 5% to 8% growth $588M Other (2) Flat $352M Adjusted diluted earnings per share $17.45 to $17.75 $16.00 Net interest expense $480M to $500M $292M Adjusted effective tax rate ~20% 20.6% Diluted weighted average shares outstanding 195.5M 195.2M Adjusted free cash flow ~$3.0B $3.0B Capital expenditures ~$900M $668M (1) Bolded figures indicate updates to guidance metrics. (2) For further detail on fiscal 2025 revised reportable segment information, please reference Exhibit 99.2 to the Company’s Current Report on Form 8-K dated November 5, 2025. (3) As reported guidance. For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation for investors. Dividend Declaration     The Company’s Board of Directors declared a quarterly cash dividend of $0.60 per common share, payable March 2, 20